Entero Therapeutics Files 8-K

TL;DR

Entero Therapeutics (formerly First Wave BioPharma) filed an 8-K on Sept 10th covering Sept 9th events.

AI Summary

Entero Therapeutics, Inc. filed an 8-K on September 10, 2024, reporting on events that occurred on September 9, 2024. The filing includes information related to Regulation FD Disclosure, Other Events, and Financial Statements and Exhibits. The company was formerly known as First Wave BioPharma, Inc. and AzurRx BioPharma, Inc.

Why It Matters

This 8-K filing provides updates on Entero Therapeutics' corporate activities and financial reporting, which are crucial for investors to understand the company's current status and regulatory compliance.

Risk Assessment

Risk Level: low — This filing is a routine 8-K reporting on corporate events and does not appear to contain significant new risks or material adverse information.

Key Players & Entities

• Entero Therapeutics, Inc. (company) — Registrant
• First Wave BioPharma, Inc. (company) — Former Company Name
• AzurRx BioPharma, Inc. (company) — Former Company Name
• September 9, 2024 (date) — Date of earliest event reported
• September 10, 2024 (date) — Filing Date

FAQ

Key Financial Figures

• $0.0001 — ch registered Common Stock, par value $0.0001 per share ENTO Nasdaq Capital Mark
• $250,000 — Assets in exchange for the issuance of $250,000 of shares of the Company's junior conve
• $500,000 — upon the Company receiving no less than $500,000 of strategic investment (the "Strategic
• $3 million — h a target of ultimately securing up to $3 million of strategic investment with the assist

Filing Documents

• tm2423688d1_8k.htm (8-K) — 30KB
• tm2423688d1_ex99-1.htm (EX-99.1) — 19KB
• 0001104659-24-098369.txt ( ) — 227KB
• fwbi-20240909.xsd (EX-101.SCH) — 3KB
• fwbi-20240909_lab.xml (EX-101.LAB) — 33KB
• fwbi-20240909_pre.xml (EX-101.PRE) — 22KB
• tm2423688d1_8k_htm.xml (XML) — 4KB

01 Regulation FD Disclosure

Item 7.01 Regulation FD Disclosure. On September 10, 2024, Entero Therapeutics, Inc., a Delaware corporation (the "Company") issued a press release announcing its entry into a binding letter of intent with DataVault Holdings, Inc. (the "Letter of Intent") (the "Press Release"). The Press Release is attached hereto as Exhibit 99.1 and is being furnished herewith. The information in this Item 7.01 of this Current Report on Form 8-K (the "Current Report") and the Press Release being furnished herewith shall not be deemed "filed" for purposes of Section 18 of the Securities Exchange Act of 1934, as amended, or otherwise in this Item 7.01 and in the Press Release attached as Exhibit 99.1 to this Current Report shall not be incorporated by reference into any filing with the Securities and Exchange Commission made by the Company, whether made before or after the date hereof, regardless of any general incorporation language in such filing.

01 Other Events

Item 8.01 Other Events. On September 9, 2024, the Company entered into the Letter of Intent with Data Vault Holdings, Inc. ("DVHI") for the licensing of certain clinical trial software owned by DVHI and associated intellectual property (the "Assets"). The Letter of Intent contemplates a worldwide exclusive license to the Assets with the right to grant sublicenses, and a right of first refusal for the Company to fully acquire the Assets in exchange for the issuance of $250,000 of shares of the Company's junior convertible preferred stock (the "Preferred Shares") priced at a price per preferred share equal to 180% of the five (5) trading day VWAP of the Company's common stock (the "Common Share Price"), immediately preceding the closing of the Proposed Transaction multiplied by 1,000 (the "Preferred Share Price"), and single digit royalties on net sales (the "Proposed Transaction"). Entry into definitive documentation for the Proposed Transaction will be conditioned upon the Company receiving no less than $500,000 of strategic investment (the "Strategic Investment"), with a target of ultimately securing up to $3 million of strategic investment with the assistance of DVHI. Contingent upon approval by the Company's shareholders, each share of junior convertible preferred stock will be convertible into shares of the Company's common stock, par value $0.0001 per share (the "Common Stock") in a one for one thousand (1:1,000) exchange (the "Conversion Ratio"), subject to certain adjustments. If, following receipt of stockholder approval, at the six month anniversary of the date of the closing of the Proposed Transaction the five (5) trading day VWAP of the Company's Common Stock immediately preceding that date (the "Six Month Anniversary Stock Price") is less than the Common Share Price, the Conversion Ratio then in effect will be automatically adjusted such that the total number of shares that are issuable upon conversion of the Preferred Shares will equal $250,000 divi

01 Financial

Item 9.01 Financial 99.1* Press Release, dated September 10, 2024 104 Cover Page Interactive Data File (embedded within the Inline XBRL document) * Furnished herewith

SIGNATURES

SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. Entero Therapeutics, Inc. September 10, 2024 By: /s/ James Sapirstein Name: James Sapirstein Title: Chief Executive Officer

View Full Filing

View this 8-K filing on SEC EDGAR